Oruka Therapeutics Aktie

Oruka Therapeutics has appointed Todd Edwards as chief commercial officer with immediate effect. Edwards joins from Arcutis Biotherapeutics and brings more than 25 years of experience in immunology and dermatology, as well as previous leadership roles at Incyte and UCB. He will lead the commercial preparation of the clinical candidates ORKA-001 and ORKA-002 for chronic skin diseases. » More on de.investing.com

Oruka Therapeutics shares rose to $109.56, hitting a 52-week high; market capitalization is about $7.24 billion, the 1-year return is 610.61% and YTD 257%. InvestingPro flags possible overvaluation but notes positives such as more cash than debt, while the company was unprofitable over the past twelve months. Analyst reactions: UBS raised its price target to $130 (buy), H.C. Wainwright reaffirmed buy with a $120 target after a licensing change with Paragon, and Piper Sandler rates it overweight with a $180 target. Oruka expects imminent release of 28-week efficacy data; earlier EVERLAST-A results showed 63.5% PASI-100 at week 16 for ORKA-001. » More on de.investing.com

Oruka Therapeutics’ stock climbed to a 52-week high of $98.19, lifting market capitalization to about $5.87 billion. The share price rose 539% over the past year, 191% year-to-date and 157% in the last six months. Several analysts continue to maintain buy ratings with price targets of $120–$180 (UBS $130, H.C. Wainwright $120, Piper Sandler $180), and some see targets up to $200, although InvestingPro considers the stock overvalued. Positive data from the EVERLAST-A study also helped: 63.5% of participants showed a significant improvement in psoriasis symptoms by week 16. » More on de.investing.com